 Amryt Pharma PLC LON:AMYT, NASDAQ:AMYT said it has received positive feedback from the American drug regulator as it seeks sign-off for its Myalept drug for use in patients with partial lipodystrophy abnormal distribution of fat. In the US, it is currently used to treat complications of leptin deficiency in patients with congenital or acquired generalized lipodystrophy. 